Novartis AG · SIX:NOVN
Novartis — Goldman Sachs 2006 Global Healthcare Conference
33 slides from Novartis's conference presentation, Jun 13, 2006
Slide 1: Goldman Sachs 2006 Global Healthcare Conference
Goldman Sachs 2006 Global Healthcare Conference June 13, 2006 James S. Shannon, M.D. Head of Pharma Development Novartis Pharma AG The following information contains certain forward-looking statements relating to the Company business, which can be identified by the use of forward-looking terminology
Slide 2: Novartis Continues to Grow Ahead of Market
Novartis Continues to Grow Ahead of Market Health care market Global quarterly value growth rates, in % Novartis Pharma 11.3 10.4 9.6 7.7 8.1 8.3 7.8 8.2 7.3 6.9 7.3 6.5 6.4 6.4 5.3 5.5 5.5 5.6 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2004 2005 2006 Source: IMS 29 Countries 3 J. Shannon – Goldman Sachs – 13 June
Slide 3: Strong Pharma Newsflow in 2006
Strong Pharma Newsflow in 2006 H1 H2 • Exforge®1 PhIII 9 • Aclasta®2 PMO-T PhIII • Rasilez®1 PhIII 9 • FTY720 MS PhII (24 months) Data • AMN107 PhII3 • Galvus®1 PhIII 9 • Sebivo PhIII 9 ®1 • FTY720 MS Ph II (18 months) 9 • NMC283 PhII9 • SOM230 PhII 9 • Rasilez®1 (US) 9 • Rasilez®1 (EU) Filings • Ga
Slide 4: Rasilez – A Breakthrough in Hypertensive Therapy
Rasilez® – A Breakthrough in Hypertensive Therapy • First new antihypertensive class in over 10 years • Direct Renin Inhibition with Rasilez® − Significantly greater BP reductions in monotherapy vs. ACEi1 − Consistent and powerful additive effect in combination − Durability and persistence of contro
Slide 5: Conclusions
Conclusions • Novartis continues to grow ahead of the market • Five submissions in Q1 2006, of which four are NMEs • Excellent new data for key late pipeline projects • Sustained high R&D productivity 9 J. Shannon – Goldman Sachs – 13 June 2006 10 J. Shannon – Goldman Sachs – 13 June 2006 5
Slide 6: Appendix – Q1 2006
Appendix – Q1 2006 11 J. Shannon – Goldman Sachs – 13 June 2006 Strong Start to 2006 with Excellent Sales and Earnings Growth Performance • Q1 Group net sales up +13% in USD, +17% in LC • Pharmaceuticals: Market share gains with net sales growth of +5% in USD, +9% in LC and significant operating mar
Slide 7: Group Operating and Net Income Expansion Outpace Sales Growth
Group Operating and Net Income Expansion Outpace Sales Growth – EPS up 32% 3 M 2006 3 M 2005 in % USD in % LC Net sales 8 301 7 341 +13 +17 Operating income 2 202 1 680 +31 as % of net sales 26.5 22.9 Net income 1 956 1 477 +32 as % of net sales 23.6 20.1 Free Cash Flow 373 - 269 * EPS (USD) 0.83 0.
Slide 8: Strong US TRx Share Growth in 2006
Strong US TRx Share Growth in 2006 US ARB March 06 TRx market segment share and growth vs. Dec 05 In %-point +0.5 -0.4 +0.6 • 9.2% Diovan TRx growth in Q1 • Value share up 1.4 ppt to 39.3%1 38.1 • Improved efficacy perception 22.4 • Best Medicare ARB coverage 14.9 • Regained SOV2 leadership • BPSZ3
Slide 9: Good Early Adoption by New Patients; Strong In-Market Brand
Good Early Adoption by New Patients Confirms High Unmet Medical Need US Exjade patients by source, Q1 2006 Sickle Cell Other New patients 29% (market 38% expansion) 40% 60% 12% 21% Thalassemia MDS Conversions from Desferal EU approval anticipated by Q3 2006 Source: Novartis estimates 17 J. Shannon –
Slide 10: Appendix – Key Pipeline Projects
Appendix – Key Pipeline Projects 19 J. Shannon – Goldman Sachs – 13 June 2006 10
Slide 11: Galvus Demonstrates Dose-proportional Reduction in HbA1c
Galvus Demonstrates Excellent, Dose-proportional Reduction in HbA1c Duration: 12 weeks Galvus 20 mg Galvus 50 mg Galvus 100 mg (n= 71) (n=72) (n=76) 0 Mean HbA1c (%) Difference to Placebo -0.2 -0.4 -0.6 -0.8 -0.82* -1.0 -0.95* -1.2 -1.2* -1.4 Baseline HbA1c 7.43 7.40 7.37 Source: Study 1202 data on
Slide 12: Galvus Powerful Add-on to Metformin; Non-Inferior vs Rosiglitazone
Phase III Confirms that Galvus® (vildagliptin) Is a Powerful Add-on Treatment to metformin Mean HbA1c (%) met1 & Galvus® 50 mg qd (n=143) met & Galvus® 50 mg bid (n=143) met & placebo (n=130) 8.6 8.4 8.2 8.0 7.8 * * * 7.6 * * * 7.4 0 -4 0 4 8 12 16 20 24 Time (weeks of treatment) 1 metformin > 1 500
Slide 13: Galvus – 1.9% HbA1c Reduction with Pioglitazone
Galvus® – 1.9% HbA1c Reduction Duration: 24 weeks Initial combination Mean HbA1c Reduction (1/5) with Pioglitazone From BL ~ 8.7% 0.0 Change from baseline in HbA1c (%) -0.5 -1.0 -1.1 -1.5 -1.4 -2.0 -1.9 -2.5 * Galvus® 100 mg daily (n=150) ITT population (intention-to-treat), Pio=Pioglitazone Pioglit
Slide 14: Galvus – High Baseline and Elderly Subgroups
Galvus® – High Baseline - 2.8% Reduction Duration: 24 weeks Initial combination Mean HbA1c Reduction (3/5) with Pioglitazone From BL ~ 10% N= 46 54 54 0.0 Change from baseline in HbA1c (%) -0.5 -1.0 -1.5 -1.5 -2.0 -1.8 -2.5 -3.0 -2.8 -3.5 * Galvus® 100 mg daily Pioglitazone 30 mg daily Pio=pioglitaz
Slide 15: Galvus – Very Obese and Weight Change
Galvus® – Very Obese -2.2% Reduction Duration: 24 weeks Initial combination BMI > 35 (5/5) with Pioglitazone Mean BL ~ 8.6% N = 27 23 32 Change from baseline in HbA1c (%) 0.0 -0.5 -1.0 -1.1 -1.1 -1.5 -2.0 -2.5 -2.2 * Galvus® 100 mg daily Pio=pioglitazone, ITT population (intention-to-treat) Pioglita
Slide 16: Galvus – Less Edema; Cardiovascular Safety
Galvus® – Less Edema Duration: 24 weeks Initial combination % Peripheral Edema with Pioglitazone 10 9.3 % peripheral edema 8 6.1 6 5.2 4 2 0 Galvus® 100 mg daily (n=150) Pio=pioglitazone, ITT population (intention-to-treat), Pioglitazone 30 mg daily (n=157) low dose combination arm is not included G
Slide 17: Overview of Filings, Study Starts and Expected Data for Galvus
Overview of Filings, Timing of Study Starts and Expected Data for Galvus® (vildagliptin) Durability Prevention Disease modification Prevention and outcome data available: 2009 and beyond T2DM Prevention of prevention CVM1 risk 2005 2006 2007 2008 2009 2010 2011 2012 Durability Combo prediabetes dura
Slide 18: Rasilez (aliskiren) – Next Generation in Blood Pressure Control
Rasilez® (aliskiren) – Next Generation in Blood Pressure and Vascular Disease Control • First oral renin inhibitor for hypertension Renin • Efficacious in monotherapy and excellent candidate for combination therapy • Potential for improved end-organ protection via control of plasma renin activity •
Slide 19: Rasilez – Consistent Double Digit Blood Pressure Response
Rasilez® – All Data Demonstrate Consistent Double Digit Blood Pressure Response Systolic Blood pressure reduction (sitting, mmHg) with Rasilez® 300mg Diastolic ® ® ® ® ® Placebo Rasilez Placebo Rasilez Placebo Rasilez Placebo Rasilez Placebo Rasilez 0 systolic systolic sys diastolic -2 -4 -6 -8 -10
Slide 20: Rasilez Decreases Early Morning Blood Pressure Surge
Rasilez® Demonstrates Marked Decrease in Early Morning Blood Pressure Surge Mean ambulatory SBP1 (mmHg) Rasilez® 300 mg, ITT2 population 155 150 145 140 Week 0 135 Week 8 130 125 120 115 0 2 4 6 8 10 12 14 16 18 20 22 24 Clock hour 1 Systolic blood pressure 2 Intent-to-treat Source: Data on file: No
Slide 21: Rasilez/ACEi Combination Offers Greater Reductions
Rasilez®/ACEi1 Combination Offers Greater Reductions in Systolic Blood Pressure… Mean change in systolic blood pressure (mmHg) from baseline at endpoint (week 8) ramipril Rasilez® Rasilez® / ramipril 10 mg 300 mg 300/10 0 -10.0 -11.0 n = 275 -12.0 -12.0 -13.0 -14.0 n = 279 -15.0 -14.7 -16.0 n = 274
Slide 22: Rasilez with HCTZ and Amlodipine
Combination of Rasilez® and HCTZ1 Gives Additional Systolic Blood Pressure Lowering Systolic blood pressure (mmHg) reduction Placebo Rasilez® HCTZ Combination 75 150 300 mg 6.25 12.5 25 mg (1) (2) (3) 0 n=195 n=183 n=180 n=194 n=176 n=173 n=173 n=195 n=183 n=188 n=187 n=186 n=184 n=185 n=183 n=188 -
Slide 23: Rasilez Tolerability Profile Comparable to Placebo
Rasilez® has a Tolerability Profile Comparable to Placebo with some Unique Elements Placebo Rasilez Rasilez/CCB Rasilez/ACEi CCB ACEi N= 781 N=2598 N= 187 N= 277 N= 357 N= 278 n (%) n (%) n (%) n (%) n (%) n (%) Any Adverse Event 314 (40.2) 1013 (39.0) 59 (31.6) 83 (30.0) 106 (29.7) 94 (33.8) Headac
Slide 24: Extensive and Innovative Outcome Program
Novartis is committed to an Extensive and Innovative Outcome Program 47 J. Shannon – Goldman Sachs – 13 June 2006 Two Key Outcomes Studies Will Define Role of Direct Renin Inhibition in Primary and Secondary Prevention AVIATOR Aliskiren in VIsceral obesity AT risk patients Outcomes Research • Prehyp
Slide 25: Overview of Filings, Study Starts and Expected Data for Rasilez
Overview of Filings, Timing of Study Starts and Expected Data for Rasilez® Large outcome studies (start) Secondary Long term outcome data prevention available: 2011 and beyond Post-MI1Pilot combination Primary therapy prevention 2005 2006 2007 2008 Filing in US Filing in EU Surrogate outcome studies
Slide 26: Exforge – Powerful BP Control Through Two Mechanisms
Exforge® - Powerful BP Control Through Two Complementary Mechanisms • Potential for best-in-class profile − Up to 43 mmHg1 reductions in systolic blood pressure − Powerful reductions in difficult to treat patients − Control rates of up to 84%2 − Lower incidence of peripheral edema vs. amlodipine alo
Slide 27: Exforge Reduction in Systolic BP in Severe Hypertension
Exforge® Delivers up to 36 mmHg Reduction in Systolic BP in Severe Hypertension Change from baseline mmHg Lis/HCTZ Exforge® Lis/HCTZ Exforge® 10-20/12.5 mg 5-10/160 mg 10-20/12.5 mg 5-10/160 mg N=66 N=64 N=66 N=64 0 Diastolic Diastolic Systolic Systolic -10 -20 -30 -27.6 -28.6 -31.8 -40 -35.8 -50 1
Slide 28: Exforge – Performance Without Amlodipine Edema
Exforge® - Performance Without Amlodipine Edema Peripheral Edema (%) Study Placebo Valsartan Amlodipine Exforge® All Controlled 10/337 23/1229 84/930 151/2613 studies 2201, 2307, (3.0%) (1.9%) (9.0%) (5.8%)1 2305, 2306 & 2308 1 P-value (Val/Aml vs. Aml in all-controlled trials) = 0.0013 55 J. Shanno
Slide 29: Portfolio Offers Physicians The Right Therapies
Portfolio Offers Physicians The Right Therapies To Meet Their Patients’ Needs • Patients not at • New patients goal on CCB, ARB or • Add-on combinations • New patients • Patients not at goal on one of the • Add-on to diuretic, components CCB, ACEi or ARB patients not at goal • Patients not at goal o
Slide 30: Good Safety Profile of FTY720 in Multiple Sclerosis
Good Safety Profile of FTY720 in Multiple Sclerosis • FTY720 was safe and well tolerated over 18 months • No confirmed cases of macular edema to date in the MS population • No cases of PML1 to date • The extension continues open-label at 1.25 mg (the 5 mg dose does not appear to provide additional b
Slide 31: FTY720 Filings Overview; Tasigna Next-Generation CML Therapy
Overview of Filings, Timing of Study Starts and Expected Data for FTY720 Start of 2-year double-blind pivotal trial in RRMS1 comparing FTY720 1.25 mg & US Filing 0.5 mg doses with placebo 2005 2006 2007 2008 2009 Start of 1-year active 18 Month Phase II comparator trial in RRMS presented at AAN2 200
Slide 32: Tasigna Registration Plans Accelerated; Planned Filings
Tasigna®1 (nilotinib, AMN107) Registration Plans Accelerated; ENACT Early Access Program Ongoing • Phase II registration trial data analysis ongoing in Glivec®-resistant/ intolerant CML - Fast track status granted by FDA - Orphan drug status granted by FDA and EMEA • ENACT (Expanding Nilotinib Acces
Slide 33: A Focused Portfolio in Attractive Market Segments
A Focused Portfolio in Attractive Market Segments Phase Business unit / Business franchise I II III & Reg Total Cardiovascular, metabolism 2 1 6 9 Oncology 5 6 5 16 Neuroscience 4 2 5 11 Respiratory & dermatology 4 4 2 10 Infectious diseases & transplantation 3 4 2 9 Ophthalmics 1 2 3 6 Arthritis, b
Novartis — Goldman Sachs 2006 Global Healthcare Conference on 6ix